The Effect of Secukinumab Treatment for Psoriasis on Serum Cytokines and Correlation with Disease Severity
Lan-Tu-Ya Wu,Zhu-Hui Qiao,Jia-Bin Tian,Lin,Su-Chun Hou,Xiao-Ming Liu
DOI: https://doi.org/10.1111/srt.13405
2023-01-01
Skin Research and Technology
Abstract:Objective: To investigate the effects of secukinumab treatment for psoriasis on different functional cytokines and inflammatory mediators in patients' serum Methods: Enzyme-linked immunosorbent assay was used to detect interleukin (IL)1 ss and IL-1RA associated with intrinsic immunity; IL-6, IL-18, and growth regulated oncogene alpha (GRO alpha) associated with neutrophils; IL-12, tumour necrosis factor (TNF)-alpha, and interferon (IFN)-gamma associated with Th1; IL-23, IL-17A, and IL-22 associated with Th17; Thymus activation regulated chemokine (TARC), IL-13, and defensin beta 2 (DEFB2) associated with Th2; Vascular endothelial growth factor (VEGF)-A and IL-10 associated with angiogenesis; and IFN-gamma associated with sepsis in the peripheral blood of 12 patients with common psoriasis treated with secukinumab and 15 healthy controls. IL-23, IL-17A, IL-22 associated with Th17; TARC, IL-13, DEFB2 associated with Th2; VEGF-A, IL-10 associated with angiogenesis and procalcitonin (PCT) associated with sepsis. The differences in expression of the above cytokines before and after treatment and the correlation with psoriasis disease severity[Psoriasis Area Severity Index(PASI) score], age, and disease duration were analyzed. Results: The mean PASI score of the enrolled patients with moderate to severe psoriasis was 21.6 +/- 11.0 before treatment and decreased to below 1 after treatment. Serum IL-6; IL-18, GRO alpha, IFN-gamma, TNF-alpha, VEGF-A, and IL-17A were significantly higher than normal. And IL-17A and IFN-gamma were positively correlated with disease duration and age, and IL-18 was positively correlated with PASI score. The expression levels of IL-6, GRO alpha, VEGF-A, IFN-gamma, TNF-alpha, IL-17A and IL-23 were significantly lower after secukinumab treatment compared with those before treatment, but the expression levels of IFN-gamma, VEGF-A, TARC, IL-13, and DEFB2 were still significantly higher than those of normal subjects after treatment Conclusions: secukinumab clears skin lesions by antagonizing IL-17A and simultaneously decreasing the expression levels of IL-6, GRO alpha, VEGF-A, IFN-gamma, TNF-alpha, IL-17A, and IL-23.